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Abstract
Obesity is a risk factor for several major cancers. Associations of weight change in
middle adulthood with cancer risk, however, are less clear. We examined the associa-
tion of change in weight and body mass index (BMI) category during middle adult-
hood with 42 cancers, using multivariable Cox proportional hazards models in the
European Prospective Investigation into Cancer and Nutrition cohort. Of 241 323
participants (31% men), 20% lost and 32% gained weight (>0.4 to 5.0 kg/year) during
6.9 years (average). During 8.0 years of follow-up after the second weight assess-
ment, 20 960 incident cancers were ascertained. Independent of baseline BMI,
weight gain (per one kg/year increment) was positively associated with cancer of the
corpus uteri (hazard ratio [HR] = 1.14; 95% confidence interval: 1.05-1.23). Compared
to stable weight (±0.4 kg/year), weight gain (>0.4 to 5.0 kg/year) was positively asso-
ciated with cancers of the gallbladder and bile ducts (HR = 1.41; 1.01-1.96), postmen-
opausal breast (HR = 1.08; 1.00-1.16) and thyroid (HR = 1.40; 1.04-1.90). Compared
to maintaining normal weight, maintaining overweight or obese BMI (World Health
Organisation categories) was positively associated with most obesity-related cancers.
Compared to maintaining the baseline BMI category, weight gain to a higher BMI cat-
egory was positively associated with cancers of the postmenopausal breast (HR = 1.19;
1.06-1.33), ovary (HR = 1.40; 1.04-1.91), corpus uteri (HR = 1.42; 1.06-1.91), kidney
(HR = 1.80; 1.20-2.68) and pancreas in men (HR = 1.81; 1.11-2.95). Losing weight to
a lower BMI category, however, was inversely associated with cancers of the corpus
uteri (HR = 0.40; 0.23-0.69) and colon (HR = 0.69; 0.52-0.92). Our findings support
avoiding weight gain and encouraging weight loss in middle adulthood.
1638 CHRISTAKOUDI ET AL.
Vetenskapsrådet; World Cancer Research
Fund (WCRF); Institut Gustave Roussy;
International Agency for Research on Cancer;
European Commission (DG-SANCO)
K E YWORD S
BMI change, cancer, middle adulthood, weight gain, weight loss
1 | INTRODUCTION
Obesity is an acknowledged risk factor for the development of
major cancers of the digestive system (oesophagus [adenocarci-
noma], gastric cardia, colon and rectum, liver, gallbladder, pan-
creas), the female reproductive system (postmenopausal breast,
corpus uteri, ovary), the thyroid, renal-cell carcinoma, meningioma
and multiple myeloma.1-3 Body mass index (BMI) at a single time
point, usually at study recruitment, is the most commonly used
measure of obesity.1 Given that in a cancer-free middle-aged popu-
lation, neither excess muscularity nor sarcopenia would be particu-
larly prominent, BMI attained at cohort entry would primarily
reflect the state of the adipose depots at this time point. Neverthe-
less, this could not distinguish between a lifelong fat excess and a
more recent fat accumulation. Weight change over time, on the
other hand, may reflect age-related metabolic changes and may
also be more relevant from a public health perspective, as it may
clarify whether lifestyle modifications in a particular period of life
could influence the risk of cancer.
From a developmental point of view, middle adulthood represents
a transitional period between early and later life, during which weight
reaches peak levels and changes relatively slowly.4 While genetic fac-
tors determining energy balance would likely present earlier in life,
during adolescence or early adulthood, lifestyle and hormonal factors,
especially peri-menopausal hormonal changes in women, would likely
determine weight change during middle adulthood. Middle adulthood
also precedes the loss of lean mass, a major contributor to weight loss
in later life.5 This raises the question whether weight loss during mid-
dle adulthood can mitigate the influence of fat accumulated during
early adulthood and whether fat accumulated during middle adult-
hood can further increase the risk of cancer.
Studies examining the association of short-term weight change in
middle adulthood with cancer risk, however, are limited and inconclu-
sive. Published reports have addressed mainly colorectal cancer, post-
menopausal breast cancer, or endometrial cancer, with only a limited
number examining cancers at other locations or a wider range of can-
cers in a single study and several focusing only on men or women. A
common constraint has been the limited number of cases, especially
for less frequent cancer types, precluding some studies from reporting
on individual cancer sites (see Supplementary Table S1 and Table S2
for summary of references).
Our aim in the current study was to examine in a large cohort, the
European Prospective Investigation into Cancer and Nutrition (EPIC),
the association of prospectively evaluated short-term changes in
weight and BMI category during middle adulthood with the risk of
cancer development in the most common tumour sites and the major
morphological subtypes.
2 | MATERIALS AND METHODS
2.1 | Study population
EPIC is a well-established, prospective, multicentre cohort examining
the association of nutrition and lifestyle with cancer and other chronic
diseases.6 Participants, mostly aged 40-70 years, from 10 European
countries were recruited between 1991 and 1999. In our study, we
excluded 280 001 participants due to missing information on weight
or confounders, extreme anthropometry or a prevalent cancer at the
second weight assessment (details shown in Figure 1), in accordance
with previous reports.7,8 We additionally restricted the analysis to
participants in the age range 40 to 70 years between baseline and the
second weight assessment, in order to focus on weight changes dur-
ing middle adulthood as opposed to changes in early adulthood or in
the elderly.
2.2 | Anthropometric assessments
Anthropometric characteristics were assessed twice: at baseline and
after a mean follow-up for weight change of 6.9 years. Weight was
mainly measured and adjusted for clothing at baseline and was self-
reported at the second assessment (see details in Supplementary
Methods).7,8 Average annual weight change, that is, weight change
rate (kg/year), was calculated by subtracting weight at baseline from
weight at the second assessment and dividing by the years between
What's new
Obesity is well known as a risk factor for multiple cancers.
What about gaining or losing weight mid-life? Here, the
authors investigated the association between cancer and
change in weight and BMI category during mid-life. Among
241,323 people, about a third gained weight and 20% lost
weight during the study. Independent of starting weight,
gaining weight was associated with several obesity-related
cancers including cancers of the gallbladder, uterus, ovary,
kidney, thyroid, breast after the menopause and in men pan-
creas. Losing weight was inversely associated with obesity-
related cancers overall, and specifically colon and uterine
cancer. The authors conclude that public health interven-
tions to support weight loss in middle age could help reduce
cancer incidence.
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the two assessments, to account for the difference in the time
interval between the centres. BMI was calculated as weight/
height2 (kg/m2).
2.3 | Cancer ascertainment
The outcome of interest was first primary cancer diagnosed after the
second weight assessment. We defined cancer types, subtypes and
morphologies according to the International Classification of Diseases
for Oncology, as specified in Supplementary Table S3 and Reference
9. Participants diagnosed with a second (or third) cancer, as well as
those with cancers with unconfirmed or behavioural codes other than
3 (malignant, primary site) were censored at the date of diagnosis
of the first cancer. We defined breast cancer as premenopausal when
the diagnosis was before 55 years of age in women premenopausal at
the second weight assessment. We defined postmenopausal breast
cancer as those diagnosed at age 55 years or later, irrespective of
menopausal status at the second weight assessment, censoring
women with breast cancer diagnosed before age 55 years. The group
of obesity-related cancers included oesophageal adenocarcinoma,
colorectal cancer (overall), cancers of the stomach (overall), liver (over-
all), pancreas, kidney, breast (postmenopausal), ovary, corpus uteri
(overall), thyroid and multiple myeloma.
Total cohort 
(n = 521 324  ca = 60 230)
Second assessment missing 
n = 180 316 (34.6%)a
Baseline exclusions (n = 24 474)
prevalent cancer or missing follow-up (n = 15 209) 
lifestyle or dietary questionnaire missing (n = 406) 
energy intake to estimated energy requirement ratio 
in top/bottom 1% of total cohort (n = 5 664) 
pregnant women (n = 284) 
weight or height measurements missing (n = 2 911)
Exclusions at the second 
assessment (n = 19 103)
cancer diagnosis or administrative 
censoring during weight 
follow-up (n = 18 086) 
smoking status or physical activity 
index missing (n = 1 017)
Greece, Utrecht, Cambridge: all
Denmark: n = 11 895 (21%) 
France: n = 14 563 (20%) 
Germany: n = 5 721 (11%) 
Italy: n = 12 685 (27%) 
Bilthoven: n = 10 470 (46%) 
Norway: n = 9 888 (27%) 
Spain: n = 742 (2%) 
Sweden: n = 17 691 (33%) 
Oxford: n = 20 302 (35%) 
Weight change follow-up period Cancer follow-up period
Extreme anthropometry (n = 981)
height <130 cm; BMI <16 kg/m2; 
waist circumference <40 or >160 cm; 
waist circumference <60 cm & BMI >25 










Final analysis dataset 
(n = 241 323; ca = 20 960)
n = 341 008
n = 316 534
n = 315 553
n = 296 450
Age restrictions (n = 55 127)
age at baseline <40 years or age at the 
second weight assessment ≥70 years
F IGURE 1 Flow diagram of participants included in the current study. Superscript “a” indicates the percentage from the number of
participants per country or centre in the total cohort; “b” indicates that the weight at baseline was measured in 68.8% of participants, except in
France and Norway, where weight and height were self-reported, and in Oxford (United Kingdom), where correcting equations were used for
self-reported weight (see details in Supplementary Methods); “c” indicates that the weight at the second assessment was self-reported in most
centres, except Umea (Sweden) and part of the cohort from Bilthoven (Netherlands), where weight was measured (4.6%) and Oxford, where
correcting equations were used for self-reported weight (7.8%); “n” is the number of participants; “ca” is the number of cancer cases; the
exclusion criteria were applied sequentially, that is, each excluded participant was counted only once, in a single exclusion step
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2.4 | Assessment of lifestyle and personal history
Participants completed detailed questionnaires on lifestyle, diet and,
in women, menstrual and reproductive history and use of exogenous
hormones at both weight assessments. Variables were harmonised to
enable compatibility between EPIC centres.6 Supplementary
Figure S1 shows the dichotomisation rules for menopausal status. We
used more recent updates for incident cancer cases and lifestyle fac-
tors compared to the earlier EPIC reports on short-term weight
change and risk of colorectal and breast cancer.7,8
2.5 | Statistical analysis
We examined weight change as a continuous variable (interpreted as
the risk associated with weight gain per one kg/year increment) and
as a categorical variable, with categories defined as weight loss (−5.0
to <−0.4 kg/year), stable weight (−0.4 to 0.4 kg/year, reference) or
weight gain (>0.4 to 5.0 kg/year), using similar cut-offs to previous
reports.7,8,10 A benefit of using fixed-value cut-offs is that they are
independent of the anthropometric characteristics of the study popu-
lation. Examining associations with weight loss and weight gain cate-
gories could highlight potential departures from linearity and enables
a more intuitive interpretation. Examining weight change as a continu-
ous variable, however, would provide more power to detect opposite
effects of weight loss and weight gain when there is a continuum in
the effect of weight change, which may suggest that the amount of
adipose tissue and the related metabolic characteristics are mechanis-
tically related to cancer.
We further examined change in BMI category, defined according to
the World Health Organisation as normal weight (NW, 18.5 to <25 kg/
m2), overweight (OW, 25 to <30 kg/m2) or obese (OB, ≥30 kg/m2). We
compared maintaining OW or OB BMI category at both assessments to
maintaining NW BMI category as reference. We further compared
changing the baseline BMI category to a higher or lower BMI category
at the second weight assessment to maintaining the corresponding
baseline BMI category as reference. We performed these comparisons
by repeating the same model three times, using each of the maintaining
BMI category groups as reference, and have shown only the compari-
sons of interest. Due to very small numbers, we excluded participants
with BMI < 18.5 kg/m2 (n = 4043) and those changing between NW
and OB BMI categories (n = 559).
We estimated hazard ratios (HR) (95% confidence intervals [CIs])
using delayed-entry Cox proportional hazards models, that is, entry
was conditional on surviving to the start of cancer follow-up. The
underlying time scale for survival analysis was age in years. The origin
of time was age zero, that is, participants were considered at risk from
birth, even though they were not observed until entering the cohort.
Entry time was age at the second weight assessment, which was the
start of cancer follow-up. Exit time was age at diagnosis of the first
incident cancer, or death, or last complete follow-up, whichever
occurred first. Models with weight change as exposure were adjusted
for baseline BMI (per 5 kg/m2 increment), as this may influence
associations with subsequent weight change. All models were
adjusted for the time interval between the two weight assessments,
to account for differences in total weight change.
We additionally stratified all models by study centre, sex (except
for sex-specific cancers) and age at the second weight assessment in
5-year categories (one category below 50 years) and adjusted for
major risk factors for cancer and weight change and potential con-
founders (see rational for selection in Supplementary Table S4):
height, energy intake (log-transformed), fruit and vegetable consump-
tion (log-transformed), attained education, smoking status and inten-
sity, alcohol consumption, physical activity index and for women also
the major determinants of oestrogen levels: menopausal status and
indicators of ever use of exogenous oestrogens, that is, oral contra-
ceptives and hormone replacement therapy (HRT) (categories are
listed in Table 1). To enable comparability, we used the same set of
adjustment variables for all cancer sites. Height, energy intake, fruit
and vegetable consumption and education were assessed at baseline
and the remaining covariates at the second weight assessment, com-
plementing missing information with baseline assessments
(Supplementary Table S5). To account for information missing at both
time points, we performed multiple sequential imputations using
chained equations (function mi impute in STATA-13) and created
m = 5 imputed datasets (Supplementary Table S6). To account for var-
iability within and between imputations, we derived the estimates of
coefficients and standard errors using Rubin's combination rules (func-
tion mi estimate in Stata 13.011). We considered as stronger evidence
for association P < .001, which corresponds to Bonferroni correction
for 50 comparisons (the approximate number of examined cancer
types), and a weaker evidence for association a P-value between .05
and .001.
For cancers observed in both sexes, we explored further hetero-
geneity by sex because some cancers have sex-specific incidence and
some published studies include only men or women. We examined
separately subgroups of men and women, additionally adjusting for
menopausal status and use of oral contraceptives and HRT in women.
In sensitivity analyses, we excluded the first 2 years of follow-up, to
mitigate possible reverse causality. To examine the influence of adjust-
ment, we derived unadjusted HR estimates retaining only the stratifica-
tion by study centre, sex (except for sex-specific cancers) and age.
We used R version 3.6.112 for management of data and results,
and STATA-13 for statistical analyses.11
3 | RESULTS
3.1 | Characteristics of study participants
Our study comprised 241 323 participants (31.3% men), with a mean
age at baseline of 51.5 years. During a mean weight follow-up of
6.9 years, 20.0% experienced weight loss and 32.2% weight gain >0.4
to 5.0 kg/year (Table 1). Fewer participants experienced weight
change to higher (13.0%) or lower (6.8%) BMI category at the second
assessment (Supplementary Table S7). Participants with weight gain
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TABLE 1 Cohort characteristics by weight change subgroup
Total
Weight loss
(−5.0 to <−0.4 kg/year)
Stable weight
(−0.4 to 0.4 kg/year)
Weight gain
(>0.4 to 5.0 kg/year)
Demographics: n (%), mean (SD)
Cohort size 241 323 48 261 (20.0) 115 429 (47.8) 77 633 (32.2)
Cancer cases 20 960 5322 (25.4) 8999 (42.9) 6639 (31.7)
Men 75 435 (31.3) 18 828 (39.0) 33 012 (28.6) 23 595 (30.4)
Age at baseline (years) 51.5 (6.3) 53.0 (6.6) 51.5 (6.1) 50.5 (6.2)
Weight follow-up period (years) 6.9 (3.2) 5.3 (2.2) 7.6 (3.3) 6.8 (3.0)
Cancer follow-up period (years) 8.0 (4.2) 9.5 (4.0) 7.2 (4.2) 8.1 (4.1)
Anthropometry: mean (SD)
Weight change (kg/year) 0.11 (0.86) −1.06 (0.70) 0.04 (0.21) 0.95 (0.58)
BMI at baseline (kg/m2) 25.5 (4.2) 28.0 (4.5) 24.6 (3.8) 25.2 (3.9)
Height (cm) 166.3 (8.9) 166.7 (9.4) 165.8 (8.7) 166.7 (8.8)
Dietary factors: median (25th-75th centile)
Energy intake (kcal/day) 2028 (1657-2472) 2023 (1648-2474) 2046 (1681-2480) 2002 (1626-2456)
Fruit and vegetables (g/day) 462 (330-636) 459 (327-643) 473 (339-644) 447 (319-621)
Alcohol consumption (g/day) 6.5 (1.2-16.7) 6.4 (0.8-17.6) 7.0 (1.5-17.0) 6.0 (1.2-15.7)
Smoking status and intensity: n (%)
Never smoked 113 518 (47.0) 22 029 (45.6) 56 963 (49.3) 34 526 (44.5)
Former: quit time >20 years 37 849 (15.7) 6789 (14.1) 19 521 (16.9) 11 539 (14.9)
Former: quit time ≤20 years 41 327 (17.1) 7819 (16.2) 17 207 (14.9) 16 301 (21.0)
Former: quit time missing 3994 (1.7) 621 (1.3) 1841 (1.6) 1532 (2.0)
Current: ≤10 cigarettes/day 18 870 (7.8) 4158 (8.6) 9008 (7.8) 5704 (7.3)
Current: >10 cigarettes/day 20 893 (8.7) 5486 (11.4) 8822 (7.6) 6585 (8.5)
Current: cigarettes missing 4872 (2.0) 1359 (2.8) 2067 (1.8) 1446 (1.9)
Physical activity index: n (%)
Inactive 51 195 (21.2) 13 015 (27.0) 21 457 (18.6) 16 723 (21.5)
Moderately inactive 79 840 (33.1) 14 899 (30.9) 38 784 (33.6) 26 157 (33.7)
Moderately active 67 856 (28.1) 11 181 (23.2) 34 186 (29.6) 22 489 (29.0)
Active 42 432 (17.6) 9166 (19.0) 21 002 (18.2) 12 264 (15.8)
Education: n (%)
None/primary school 73 471 (30.4) 19 714 (40.8) 31 197 (27.0) 22 560 (29.1)
Secondary/technical school 102 066 (42.3) 17 436 (36.1) 50 387 (43.7) 34 243 (44.1)
University/longer education 59 582 (24.7) 10 139 (21.0) 30 973 (26.8) 18 470 (23.8)
Missing information 6204 (2.6) 972 (2.0) 2872 (2.5) 2360 (3.0)
Menopausal status: n (%)a
Premenopausal 30 665 (18.5) 6234 (21.2) 12 473 (15.1) 11 958 (22.1)
Postmenopausal 135 223 (81.5) 23 199 (78.8) 69 944 (84.9) 42 080 (77.9)
Oral contraceptives: n (%)a
Never used 58 549 (35.3) 12 286 (41.7) 28 806 (35.0) 17 457 (32.3)
Ever used 105 184 (63.4) 16 927 (57.5) 52 589 (63.8) 35 668 (66.0)
Missing information 2155 (1.3) 220 (0.7) 1022 (1.2) 913 (1.7)
Hormone replacement therapy: n (%)a
Never used 77 135 (46.5) 16 217 (55.1) 35 706 (43.3) 25 212 (46.7)
Ever used 80 617 (48.6) 11 624 (39.5) 43 120 (52.3) 25 873 (47.9)
Missing information 8136 (4.9) 1592 (5.4) 3591 (4.4) 2953 (5.5)
Abbreviations: SD, standard deviation;
aUsed as covariates in women; all covariates were derived from questionnaires at the second weight assessment, except from education, energy intake and
fruit and vegetable consumption, which were derived from questionnaires at baseline; n (%), number of individuals (percentage from total number in
category or from total cohort size and cancer cases).
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TABLE 2 Weight change in relation to cancer risk
Weight gain (cont.)a
(per 1 kg/year increment)
Weight loss (cat.)b




(>0.4 to 5.0 kg/year)
Cancer type/^subtype Cases HR (95% CI) Cases HR (95% CI) Cases Cases HR (95% CI)
Any cancer (overall) 20 960 1.00 (0.99-1.02) 5322 1.00 (0.97-1.04) 8999 6639 1.02 (0.99-1.05)
Obesity-related cancers 9569 1.03 (1.00-1.05)* 2223 0.98 (0.93-1.03) 3977 3024 1.08 (1.03-1.13)*
Head and neck
Head and neck (overall) 381 0.94 (0.85-1.06) 107 1.07 (0.83-1.38) 154 120 1.01 (0.79-1.29)
^Mouth and oropharynx 190 0.85 (0.73-1.00)* 55 1.15 (0.80-1.66) 76 59 0.98 (0.69-1.38)
^Larynx 126 1.03 (0.85-1.25) 34 0.98 (0.63-1.53) 52 40 1.05 (0.69-1.59)
Digestive system
Oesophagus (overall) 157 1.02 (0.86-1.20) 42 0.78 (0.52-1.16) 72 43 0.73 (0.50-1.08)
^Oesophageal adenocarcinoma 57 1.16 (0.89-1.52) 17 0.98 (0.50-1.90) 22 18 0.99 (0.53-1.86)
^Oesophageal SCC 71 0.88 (0.68-1.14) 19 0.75 (0.42-1.36) 35 17 0.57 (0.32-1.04)
Stomach (overall) 354 0.95 (0.85-1.07) 99 0.92 (0.71-1.21) 153 102 0.91 (0.71-1.18)
^Gastric adenocarcinoma 165 0.90 (0.76-1.06) 52 1.32 (0.90-1.95) 63 50 1.10 (0.76-1.61)
Colorectal (overall) 2381 0.98 (0.94-1.03) 629 0.98 (0.88-1.09) 1007 745 1.03 (0.93-1.13)
^Colon 1503 0.99 (0.94-1.05) 396 0.96 (0.84-1.09) 624 483 1.07 (0.94-1.20)
^Rectum and
rectosigmoid junction
878 0.97 (0.90-1.05) 233 1.02 (0.86-1.21) 383 262 0.96 (0.82-1.13)
Liver and bile ducts (overall) 323 1.11 (0.99-1.24) 96 1.20 (0.90-1.59) 111 116 1.43 (1.10-1.86)*
^Hepatocellular carcinoma 77 0.85 (0.67-1.08) 31 1.95 (1.11-3.43)* 24 22 1.24 (0.69-2.23)
^Gallbladder and bile ducts 194 1.20 (1.03-1.39)* 47 0.88 (0.60-1.29) 72 75 1.41 (1.01-1.96)*
Pancreas 549 0.95 (0.87-1.04) 156 1.05 (0.85-1.30) 228 165 1.03 (0.84-1.27)
Respiratory system
Lung (overall) 1560 0.94 (0.88-0.99)* 453 1.23 (1.09-1.40)* 614 493 1.07 (0.94-1.20)
^Lung adenocarcinoma 603 0.98 (0.89-1.07) 157 1.12 (0.91-1.38) 251 195 1.07 (0.89-1.30)
^Lung SCC 296 0.85 (0.75-0.96)* 95 1.28 (0.97-1.69) 121 80 0.83 (0.62-1.10)
^Lung small-cell carcinoma 182 1.05 (0.90-1.24) 54 1.16 (0.80-1.68) 70 58 1.19 (0.83-1.69)
Urinary system
Kidney 429 1.06 (0.96-1.17) 119 0.95 (0.74-1.22) 171 139 1.10 (0.88-1.38)
Renal pelvis and ureter 60 1.27 (0.97-1.68) 14 0.71 (0.36-1.38) 28 18 0.93 (0.51-1.70)
Bladder 643 0.98 (0.90-1.06) 185 1.07 (0.88-1.31) 253 205 1.03 (0.85-1.24)
Reproductive system
Prostate 3751 1.02 (0.98-1.06) 960 0.93 (0.86-1.01) 1695 1096 0.95 (0.87-1.02)
Breast (female) (overall) 4179 1.03 (0.99-1.06) 886 0.98 (0.90-1.07) 1858 1435 1.06 (0.98-1.13)
^Breast (premenopausal) 377 0.98 (0.88-1.09) 82 0.98 (0.73-1.30) 159 136 0.86 (0.68-1.09)
^Breast (postmenopausal) 3802 1.03 (1.00-1.07) 804 0.98 (0.90-1.07) 1699 1299 1.08 (1.00-1.16)*
Ovary 500 1.01 (0.91-1.11) 111 0.93 (0.73-1.19) 221 168 1.00 (0.81-1.22)
Corpus uteri 688 1.14 (1.05-1.23)* 160 0.91 (0.74-1.12) 277 251 1.19 (1.00-1.41)
^Uterine adenocarcinoma 188 1.23 (1.06-1.43)* 39 0.87 (0.57-1.32) 74 75 1.23 (0.89-1.71)
^Endometrioid adenocarcinoma 401 1.12 (1.01-1.24)* 91 0.84 (0.64-1.10) 169 141 1.14 (0.91-1.43)
Cervix uteri 98 0.96 (0.78-1.17) 24 0.81 (0.47-1.37) 43 31 0.90 (0.56-1.44)
Anogenital 132 0.99 (0.82-1.21) 45 1.61 (1.04-2.49)* 47 40 1.18 (0.77-1.82)
Skin
Skin SCC 727 0.87 (0.80-0.95)* 192 0.99 (0.82-1.19) 347 188 0.78 (0.65-0.93)*
Melanoma 858 0.97 (0.89-1.05) 201 1.07 (0.89-1.28) 375 282 1.01 (0.87-1.19)
Nervous and endocrine system
Brain and CNS 309 0.94 (0.83-1.07) 80 0.90 (0.67-1.20) 143 86 0.80 (0.61-1.05)
Thyroid 232 1.11 (0.96-1.27) 56 1.23 (0.85-1.77) 89 87 1.40 (1.04-1.90)*
Haematopoietic system
Leukaemia (overall) 695 1.00 (0.92-1.09) 169 0.94 (0.77-1.15) 297 229 1.02 (0.85-1.21)
^Multiple myeloma 254 1.05 (0.92-1.21) 58 0.86 (0.62-1.21) 111 85 1.01 (0.76-1.35)
Lymphoma (overall) 549 0.98 (0.89-1.08) 139 1.00 (0.81-1.25) 241 169 0.92 (0.75-1.12)
^Non-Hodgkin lymphoma 466 0.98 (0.88-1.09) 121 1.05 (0.83-1.33) 201 144 0.96 (0.77-1.19)
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were more likely younger (Table 1). Participants with stable weight
had the lowest BMI at baseline (mean = 24.6 kg/m2). Participants with
weight loss had considerably higher BMI at baseline (mean = 28.0 kg/
m2) and were more likely men, current smokers or inactive. Energy,
fruit, vegetable and alcohol consumption were comparable between
the groups with weight loss, weight gain or stable weight. Women
who lost weight were less likely to have ever used HRT. Compared to
women, men were more likely smokers (either former or current), with
higher baseline BMI, higher energy intake and alcohol consumption,
but lower fruit and vegetable consumption (Supplementary Table S8).
In total, 20 960 incident cancers were diagnosed during a mean
follow-up of 8.0 years (Supplementary Table S9). Participants diag-
nosed with cancer had a higher baseline BMI (mean = 26.2 kg/m2)
than the cohort overall and a larger proportion experienced weight
loss (25.4%). Participants with hepatocellular carcinoma (HCC) had the
highest baseline BMI (mean = 28.3 kg/m2) and the largest proportion
with weight loss (40.3%). Participants from Denmark, Spain and Swe-
den contributed 65.7% of all cancer cases.
3.2 | Associations between weight change and
cancer risk independent of baseline BMI
The main analyses are presented in Table 2 and the subgroup analyses
by sex in Supplementary Table S10.
Obesity-related cancers showed positive associations with weight
gain, independent from baseline BMI. Compared to the stable weight
category (−0.4 to 0.4 kg/year), weight gain (>0.4 to 5.0 kg/year) was
positively associated with obesity-related cancers overall (HR: 1.08;
95% CI: 1.03, 1.13) and specifically with cancers of the gallbladder
and bile ducts (HR: 1.41; 95% CI: 1.01, 1.96), postmenopausal breast
(HR: 1.08; 95% CI: 1.00, 1.16) and thyroid (HR: 1.40; 95% CI: 1.04,
1.90). Weight gain as a continuous variable (per one kg/year incre-
ment) was also positively associated with obesity-related cancers
overall (HR: 1.03; 95% CI: 1.00, 1.05) and specifically with cancers of
the gall bladder and bile ducts (HR: 1.20; 95% CI: 1.03, 1.39), corpus
uteri (HR: 1.14; 95% CI: 1.05, 1.23) and thyroid in men (HR: 1.55;
95% CI: 1.08, 2.23). The only exception among obesity-related can-
cers was HCC, which was positively associated with weight loss (−5.0
to <−0.4 kg/year) compared to the stable weight category (HR: 1.95;
95% CI: 1.11, 3.43) and in women was inversely associated with
weight gain as a continuous variable (per one kg/year increment)
(HR: 0.59; 95% CI: 0.38, 0.93).
Squamous cell carcinomas (SCC), on the contrary, showed inverse
associations. Weight gain as a continuous variable (per one kg/year
increment) was inversely associated with cancers of the mouth and oro-
pharynx (HR: 0.85; 95% CI: 0.73, 1.00), lung SCC (HR: 0.85; 95% CI:
0.75, 0.96), skin SCC (HR: 0.87; 95% CI: 0.80, 0.95) and oesophageal
SCC in women (HR: 0.62; 95% CI: 0.39, 0.99). Further, compared to the
stable weight category, weight gain (>0.4 to 5.0 kg/year) was inversely
associated with skin SCC (HR: 0.78; 95% CI: 0.65, 0.93), while weight
loss (−5.0 to <−0.4 kg/year) was positively associated with anogenital
cancers (HR: 1.61; 95% CI: 1.04, 2.49).
Lung adenocarcinoma showed complex sex-specific associations.
In women, the association was inverse for weight gain as a continuous
variable (per one kg/year increment) (HR: 0.84; 95% CI: 0.74, 0.96)
and was positive for weight loss (−5.0 to <−0.4 kg/year) compared to
the stable weight category (HR: 1.33; 95% CI: 1.02, 1.73), while in
men the association was positive both for weight gain as a continuous
variable (per one kg/year increment) (HR: 1.15; 95% CI: 1.00, 1.33)
and for weight gain (>0.4 to 5.0 kg/year) compared to the stable
weight category (HR: 1.34; 95% CI: 1.01, 1.77). Weight gain as a con-
tinuous variable (per one kg/year increment) showed an additional
positive association with cancers of the renal pelvis and ureter in
women (HR: 1.64; 95% CI: 1.08, 2.50), while in men weight gain (>0.4
to 5.0 kg/year) compared to the stable weight category showed
inverse associations with cancers of the brain and central nervous sys-
tem (CNS) (HR: 0.58; 95% CI: 0.38, 0.88) and non-Hodgkin lymphoma
(HR: 0.71; 95% CI: 0.50, 1.00).
3.3 | Associations between change in BMI
category and cancer risk
The main analyses are presented in Table 3 and the subgroup analyses
by sex in Supplementary Table S11.
Compared to maintaining NW BMI (18.5 to <25 kg/m2),
maintaining OW (25 to <30 kg/m2) or OB BMI category (≥30 kg/m2)
at both assessments was positively associated with obesity-related
cancers overall and individually with oesophageal adenocarcinoma,
HCC, cancers of the colon, gallbladder and bile ducts, pancreas, kid-
ney, postmenopausal breast, ovary, corpus uteri and thyroid, but not
Abbreviations: CI, confidence interval; HR, hazard ratio; SCC, squamous cell carcinoma; premenopausal, breast cancer diagnosed at age < 55 years in
women premenopausal at the second weight assessment; postmenopausal, breast cancer diagnosed at age ≥ 55 years, irrespective of menopausal status at
the second weight assessment; obesity-related cancers, oesophageal adenocarcinoma, cancers of the stomach (overall), colorectum (overall), liver (overall),
pancreas, kidney, postmenopausal breast, ovary, corpus uteri (overall), thyroid and multiple myeloma.
aHR estimates were obtained from Cox proportional hazards models including weight change as a continuous variable (interpreted as the risk associated
with weight gain per one kg/year increment), stratified by study centre, sex (except for sex-specific cancers) and age at the second weight assessment and
adjusted for baseline body mass index (per 5 kg/m2 increment), height, education, energy intake, fruit and vegetable consumption (assessed at baseline), as
well as for smoking status and intensity, physical activity, alcohol consumption and for female cancers also menopausal status (except premenopausal
cancer), ever using oral contraceptive and hormone replacement therapy (at the second assessment) and time interval between the two weight assessments.
bThe models included weight change as a categorical variable and compared weight loss or weight gain categories to stable weight (−0.4 to 0.4 kg/year) as
reference, with stratification and adjustments as in footnote a.
*P < .05. **P < .001.
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with cancers of the stomach, rectum and rectosigmoid junction or
multiple myeloma. Compared to maintaining the baseline BMI cate-
gory, weight gain from NW to OW BMI category was positively asso-
ciated with obesity-related cancers overall (HR: 1.12; 95% CI: 1.04,
1.22) and specifically with cancers of the postmenopausal breast (HR:
1.19; 95% CI: 1.06, 1.33), ovary (HR: 1.40; 95% CI: 1.04, 1.91), corpus
uteri (HR: 1.42; 95% CI: 1.06, 1.91) and pancreas in men (HR: 1.81;
95% CI: 1.11, 2.95), while weight gain from OW to the OB BMI cate-
gory was similarly positively associated with obesity-related cancers
overall (HR: 1.18; 95% CI: 1.06, 1.31) and specifically with kidney can-
cer (HR: 1.80; 95% CI: 1.20, 2.68). In accordance, weight loss from OB
to OW BMI category was inversely associated with obesity-related
cancers overall (HR: 0.87; 95% CI: 0.77, 0.98) and specifically with
cancer of the corpus uteri (HR: 0.40; 95% CI: 0.23, 0.69), while weight
loss from OW to NW BMI category was inversely associated with
colon cancer (HR: 0.69; 95% CI: 0.52, 0.92).
At the same time, compared to maintaining NW BMI, maintaining
OW or OB BMI category at both assessments was inversely associated
with SCC of the oesophagus, lung and skin, while there was a positive
association with lung SCC when losing weight from OW to NW, com-
pared to maintaining OW BMI category (HR: 1.63; 95% CI: 1.01, 2.63).
Associations with lung adenocarcinoma were in opposite directions for
women and men. In women, compared to maintaining NW BMI cate-
gory, there was an inverse association when gaining weight to OW BMI
category (HR: 0.62; 95% CI: 0.39, 1.00), as well as when maintaining
OW (HR: 0.69; 95% CI: 0.52, 0.92) or OB BMI category (HR: 0.47; 95%
CI: 0.29, 0.76), while in men, there was a positive association when
gaining weight from OW to OB, compared to maintaining OW BMI cat-
egory (HR: 1.79; 95% CI: 1.05, 3.05). In women, compared to
maintaining NW, maintaining OW BMI category was additionally posi-
tively associated with cancers of the brain and CNS (HR: 1.51; 95% CI:
1.03, 2.21) and lymphoma overall (HR: 1.34; 95% CI: 1.00, 1.79).
The evidence for all observed associations with change in weight or
BMI category was considered weak, with P-values between .05 and .001.
3.4 | Sensitivity analyses
Removing individuals with less than 2 years of follow-up attenuated
the positive association of weight loss (−5.0 to <−0.4 kg/year) with
HCC (HR: 1.35; 95% CI: 0.70, 2.61) and indicated an inverse associa-
tion of weight gain (>0.4 to 5.0 kg/year) with prostate cancer (HR:
0.92; 95% CI: 0.85, 1.00), compared to the stable weight category, but
did not materially alter other associations. Compared to the
unadjusted models, adjustment for smoking status and intensity and
other confounders did not attenuate the inverse associations with
cancers with SCC morphology (Supplementary Tables S12 and S13).
4 | DISCUSSION
We report positive associations of weight gain in middle adulthood with
obesity-related cancers overall and individually with cancers of the
gallbladder and bile ducts, postmenopausal breast, corpus uteri and thy-
roid, which were independent of associations with baseline BMI. Com-
pared to maintaining NW, maintaining OW or OB BMI category was
positively associated with most obesity-related cancers. Gaining weight to
a higher BMI category was also positively associated with obesity-related
cancers overall and specifically with cancers of the kidney, postmeno-
pausal breast, ovary and corpus uteri, while losing weight to a lower BMI
category was inversely associated with obesity-related cancers overall and
specifically with cancers of the colon and corpus uteri. Cancers with SCC
morphology of the upper aerodigestive tract, lung and skin showed
inverse associations with weight gain and with maintaining OW or OB
BMI category. Half of our study participants maintained stable weight,
with comparable proportions gaining or losing >0.4 to 5 kg/year and only
one in five changing their baseline BMI category. Our findings are thus
compatible with reports of weight change trajectories, indicating that in
middle adulthood weight reaches a plateau and the direction of weight
change switches gradually from weight gain in early adulthood to weight
loss in late adulthood.4
The major mechanisms linking obesity to cancer are excess
oestrogens, which are generated via aromatase in adipocytes; high
levels of leptin, which promotes the migration and invasion of cancer
cells; low levels of adiponectin, which has anti-inflammatory, anti-
proliferative and pro-apoptotic properties; chronic low-grade inflam-
mation accompanied by insulin resistance and hyperinsulinemia, which
facilitate tumour growth and progression.13 Although obesity-related
mechanisms are often examined with respect to attained weight, they
can also be influenced by short-term weight changes. Thus, short-
term weight gain can be associated with increased leptin, pro-
inflammatory markers and insulin resistance,14,15 while weight loss
can be associated with lower leptin, lower circulating oestrogens and
improved insulin sensitivity.15-17 Nevertheless, the overall effect of
short-term weight change is not always predictable and can differ
according to baseline weight. For example, in normal-weight individ-
uals, high leptin resulting from moderate short-term weight gain
induces adiponectin expression, while in individuals with established
obesity, leptin signalling is impaired and hinders a concomitant
adiponectin increase.18 Adipose-derived factors, especially
oestrogens, can also act and interact differentially in individual tissues.
Thus in breast adipose tissue, leptin stimulates aromatase activity,
which contributes to higher oestrogen levels and both promote breast
cancer development,19 while in HCC cell lines, oestradiol induces apo-
ptosis and opposes the oncogenic actions of leptin.20 Furthermore,
obesity is not only accompanied by higher oestrogen levels but also
by gonadal dysfunction, with higher testosterone levels in OB women
and lower in OB men and changes in opposite directions with weight
loss.21 An additional constraint is the lack of studies specifically exam-
ining the dynamics of adipose-derived factors after weight changes in
middle adulthood.
A notable pattern in our findings was the positive association of
weight change in middle adulthood specifically with cancers promoted
by oestrogens, either female specific or with higher incidence in
women, despite the fact that maintaining OW or OB BMI category
was positively associated with most obesity-related cancers. In
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agreement with our findings, observational studies have consistently
reported positive associations of weight gain in middle adulthood with
cancers of the postmenopausal breast7,10,22,23 and corpus uteri10,22,24
and inverse associations with weight loss, especially when
intentional,25 sustained,26 or after bariatric surgery.27 No associations,
however, have previously been reported with ovarian cancer.10,25 An
involvement of weight change in oestrogen-driven cancers of the
female reproductive system is not surprising, given that adipose-
derived oestrogens gain prominence in postmenopausal women,
when gonadal oestrogen production decreases.13 Nevertheless,
although ERα activation promotes cancer development in the breast,
ovary and corpus uteri, differences exist in the local regulation of ER
expression,28 oestrogen signalling29 and aromatase transcription.30
Leptin signalling pathways also differ.31 This may partly explain the
differences in the association patterns that we observed. While there
was a consistent dose-response relationship between weight gain as a
continuous variable and the risk of cancer of the corpus uteri, with
both higher risk for weight gain and lower risk for weight loss com-
pared to maintaining the baseline BMI category, only weight gain was
associated with cancers of the ovary and postmenopausal breast, with
no clear indication for lower risk with weight loss. Further, the hith-
erto unreported positive associations of weight gain with cancers of
the gallbladder and bile ducts and the thyroid, which have higher inci-
dence in women, are also compatible with a cancer promoting role of
oestrogens. Oestrogens can stimulate the growth and migration of
thyroid cancer stem cells,32 while ERβ expression is higher in gallblad-
der cancers compared to normal tissues and is associated with worse
prognosis.33 Furthermore, although the incidence of renal cell carci-
noma is higher in men, oestradiol can promote the progression of
renal cancer cells via activation of ERβ34 and a positive association
with weight gain has previously been reported in women.22
On the other hand, cancers of the digestive system (colon, pan-
creas and liver), for which oestrogens can have protective effects, did
not show prominent positive associations with weight gain in middle
adulthood, despite clear positive associations with maintaining OW or
OB BMI category. In agreement with our findings, published epidemi-
ological studies have provided little evidence for positive associations
of short-term weight gain with colorectal cancer,8,10,22,35 but an
inverse association has been reported with intentional weight loss,25
which we have observed for weight loss from OW to NW BMI cate-
gory. Although mechanistic studies have shown that colonocyte pro-
liferation increases with weight gain and decreases with weight loss,36
it has also been suggested that weight gain in middle adulthood is less
hazardous for colorectal cancer compared to weight gain during early
adulthood.8,37 This might be related to different causes of weight gain
or a different balance between the pro-carcinogenic and anti-
proliferative properties of adipose-derive factors during different
periods of adulthood. Thus, while leptin enhances the adhesion and
invasion of colorectal cancer cells,38 activation of ERβ by oestrogens
is largely considered protective, as ERβ is lost from colon cancer cells
during tumour progression39 and HRT use is inversely associated with
colorectal cancer risk.40 Oestrogens can similarly show discordant
effects with other adipose-derived factors for the development of
pancreatic cancer. Thus, a positive association between prediagnostic
levels of leptin and pancreatic cancer has been reported in men,41
while exogenous oestrogens have shown a protective effect against
pancreatic cancer in women.42 This may explain the inconclusive find-
ings of observational studies for pancreatic cancer, either providing lit-
tle evidence for association in women,25 or showing positive
associations with recent weight gain,10 which we have observed with
a limited number of cases in men. Further in agreement with our find-
ings, a positive association of recent unintentional weight loss with
the risk of liver cancer in women has been reported.25 Although acti-
vation of both ERα and ERβ has shown protective effects in HCC
cells20 and oestrogen levels decrease with weight loss,17 unintentional
weight loss is a major clinical feature of cancer and reverse causality
would more likely explain the positive association of short-term
weight loss with HCC observed in our study.
A further notable pattern in our findings was the inverse asso-
ciation between weight gain and cancers with SCC morphology.
Cancers of the upper aero-digestive tract and lung with SCC mor-
phology are all associated with smoking and have shown inverse
association with BMI, considered controversial in the literature,
but studies examining associations with weight change are lim-
ited. While a recent umbrella meta-analysis reported “highly sug-
gestive” evidence for inverse associations of BMI with
oesophageal SCC and lung cancer overall,1 the International
Agency for Research on Cancer considers the evidence insuffi-
cient2 and the World Cancer Research Fund has acknowledged a
positive association of OW and obesity with cancers of the
mouth, pharynx and larynx.3 Furthermore, a recent Mendelian
randomisation study has provided evidence for positive associa-
tions of BMI with lung SCC and small-cell carcinoma, but not with
lung adenocarcinoma.43 Residual confounding from smoking,
despite a detailed adjustment for smoking status and intensity,
and reverse causality are possible explanations for inverse associ-
ations, but removing the first 2 years of follow-up had no material
influence, making a reverse causality from cancer cachexia less
likely. In addition, we found little evidence for inverse associa-
tions with lung small cell carcinoma, which is also strongly associ-
ated with smoking, but observed a hitherto unreported inverse
association of weight gain with skin SCC. Intriguingly, recent
mechanistic studies suggest a protective effect of oestrogens for
cancers with SCC morphology. Thus, ERα is overexpressed in
human papilloma virus positive (HPV+) oropharyngeal cancers and
oestrogens suppress viral gene expression and growth of HPV+
cells.44 Further, oestradiol suppresses in a dose-dependent man-
ner the proliferation of oesophageal SCC cells45 and, in women,
HRT is inversely associated while menopause is positively associ-
ated with oesophageal SCC.46 Furthermore, female mice have
shown higher skin tumour resistance compared to male mice, with
ovariectomy resulting in overexpression of ERα, suppression of
ERβ and increased susceptibility to skin SCC, comparable to male
mice.47 In vitro, increased ERβ expression or stimulation with
oestrogen agonists inhibits proliferation of SCC cells and pro-
motes squamous cell differentiation.48 It is thus possible that
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adipose-derived oestrogens mitigate the risk of tumours with SCC
morphology.
Supplementary Discussion includes comments on cancers with
sex-specific or limited evidence for association with weight change
and a comparison of the current with previous EPIC studies on weight
change and cancer risk.
A major strength of our study is the prospective assessment of
weight. EPIC is also a large multicentre cohort, including both men
and women from several European countries, with a variety of life-
styles and dietary patterns and a sizeable number of incident cancer
cases. This provided large statistical power for analyses of the most
common cancer sites, although statistical power was limited for the
less common cancer sites, especially for change in BMI category and
for the sex-specific analyses.
A major limitation of our study is that the second weight assess-
ment was mostly self-reported, which can result in underestimating
weight, especially in heavier individuals.49 Therefore, weight gain may
have been underestimated and weight loss overestimated, with no
obvious way to anticipate in which direction associations were
biased.50 Although for most centres we had no centre-specific equa-
tions to predict measured from self-reported weight, examining the
application of correcting equations has shown that they improve the
distribution of BMI but do not remove the bias in the estimates for
associations between self-reported BMI and different disease out-
comes.51 Nevertheless, BMI categories based on measured and self-
reported weight were in good agreement in EPIC-Norway (Cohen's
kappa = 0.73).52 A further limitation was that there were only two
weight assessments and we could not explore fluctuations in weight
and weight cycling, that is, alternating gain and loss, which have
been associated with a higher risk of cancer.27 Furthermore, we
focused on change in weight and BMI category, whereas other
anthropometric parameters, for example, central rather than overall
adiposity, could be relevant for cancer aetiology.1 The large propor-
tion of missing values at the second assessment of waist circumfer-
ence limited this evaluation in EPIC. Finally, we could not
distinguish between intentional and unintentional weight loss,
which can have different effects,25 but we examined the possibility
of reverse causality by excluding participants with less than 2 years
follow-up after the second weight assessment. The caveats of this
approach are that removing individuals could potentially introduce
selection bias, while removing cancer cases would reduce statistical
power and subclinical cancer development may take longer than
2 years.
5 | CONCLUSIONS
Our findings confirm a positive association between maintaining
OW or OB BMI in middle adulthood and most obesity-related can-
cers. In addition, independent of baseline BMI, weight gain in middle
adulthood was positively associated with obesity-related cancers
overall and specifically with cancers of the gallbladder and bile
ducts, postmenopausal breast, corpus uteri and thyroid. Weight gain
to a higher BMI category was also positively associated with
obesity-related cancers overall and specifically with cancers of the
kidney, postmenopausal breast, ovary, corpus uteri and in men
pacreas, while weight loss to a lower BMI category was inversely
associated with obesity-related cancers overall and specifically with
cancers of the colon and corpus uteri. Our observations support
public health interventions in middle adulthood advocating mainte-
nance of BMI in the NW category, avoidance of weight gain, and
weight loss when BMI is high, in order to reduce the risk of some
obesity related cancers.
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